Pramote Hochareon, M.D., Ph.D.
NIRVAMED, INC
Abstract
As a Thai-American MedTech startup, NirvaMed is developing an innovative technology platform designed to enhance the safety and efficacy of percutaneous coronary interventions (PCI) for high-risk patients. Our focus is on advancing catheter-based solutions that seamlessly integrate into existing clinical workflows while providing new therapeutic and protective functions.
Our core technology, the coronary sinus (CS) catheter, is designed to deliver dual applications. First, it supports heart-cooling therapy by leveraging localized hypothermia through the coronary venous system to treat heart attack patients. This novel approach cools the left ventricular (LV) wall in a targeted manner without disrupting standard PCI procedures. Our catheter's unique design, featuring multifunctional balloons and multiple lumens, accommodates variations in coronary venous anatomy, ensuring precise treatment delivery.
Second, the same platform is being applied to contrast media removal, offering a game-changing solution for high-risk PCI patients with kidney disease. By capturing and removing toxic contrast media before it enters systemic circulation, we minimize the risk of contrast-induced nephropathy (CIN), making PCI safer for patients with chronic kidney conditions. This dual-function technology not only simplifies the treatment of complex cardiac cases but also expands the range of patients eligible for PCI procedures.
We are collaborating with world-class research institutions like the Visible Heart Lab at the University of Minnesota, ensuring our technology is validated through advanced testing, including cadaver heart studies. With this platform, NirvaMed is uniquely positioned to address critical gaps in cardiovascular care while significantly reducing costs and risks.
For prospective investors, this platform presents a scalable, globally relevant solution with a clear market need. Join us to explore how NirvaMed is shaping the future of cardiovascular intervention, with opportunities for strategic investment in a technology that’s set to disrupt the field.
Short biography:
Pramote was a senior scientist at Boston Scientific, leading several critical concept & product development projects, e.g. arrhythmia detection and heart failure monitoring technologies. With his leadership, NirvaMed was recognized as the finalist of Minnesota and Wisconsin business plan contests. Pramote received M.D. and Ph.D. in Bioengineering in The Artificial Heart. He also won international research grants.Currently Pramote is CEO, Director of NIRVAMED, INC.
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.